Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey

作者全名："Zhang, Tingting; Meng, Chao; He, Wei; Xu, Tao; Yang, Yi; Tu, Chongqi; Zhang, Ling; Sun, Xiaofeng; Zhu, Chunrong; Dang, Xueyi; Wang, Ke; Chen, Chuan; Yan, Xiong; Xu, Huiting; Huang, Le; Jiang, Enlai; Xia, Feng; Zhou, Xinming; Zhou, Shunkai; Zang, Weidong; Li, Xifeng; Zhang, Jin; Zheng, Jiaping; Xin, Jianjun; Huang, Bin; Zhu, Guopei; Zhu, Jiexiang; Liang, Jun"

作者地址："[Zhang, Tingting; Meng, Chao; Liang, Jun] Peking Univ, Int Hosp, Dept Oncol, 1 Life Pk Rd,Life Sci Pk Zhongguancun, Beijing 102206, Peoples R China; [He, Wei] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China; [Xu, Tao] Shandong Prov Hosp, Dept Gastrointestinal Surg, Jinan, Peoples R China; [Yang, Yi] Harbin Med Univ, Dept Intervent Radiol, Canc Hosp, Harbin, Peoples R China; [Tu, Chongqi] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Peoples R China; [Zhang, Ling] Henan Canc Hosp, Dept Hepatobiliary Surg, Zhengzhou, Peoples R China; [Sun, Xiaofeng] Nanjing Med Univ, Affiliated Canc Hosp, Dept Internal Med, Nanjing, Peoples R China; [Zhu, Chunrong] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China; [Dang, Xueyi] Shanxi Canc Hosp, Dept Hepatobiliary Surg, Taiyuan, Peoples R China; [Wang, Ke] Tianjin Med Univ, Dept Gynecol Oncol, Canc Inst & Hosp, Tianjin, Peoples R China; [Chen, Chuan] Army Med Ctr, Daping Hosp, Dept Orthoped, Chongqing, Peoples R China; [Yan, Xiong] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary, Chongqing, Peoples R China; [Xu, Huiting] Hubei Canc Hosp, Dept Abdominal Oncol, Wuhan, Peoples R China; [Huang, Le] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China; [Jiang, Enlai] Army Med Univ, Affiliated Hosp 2, Dept Gen Surg, Chongqing, Peoples R China; [Xia, Feng] AMU, Southwest Hosp, Dept Hepatobiliary, Chongqing, Peoples R China; [Zhou, Xinming] Xijing Hosp, Dept Gastroenterol, Xian, Peoples R China; [Zhou, Shunkai] Peoples Liberat Army, Hosp 900, Dept Thorac Surg, Joint Serv Support Force, Fuzhou, Peoples R China; [Zang, Weidong] Fujian Canc Hosp, Dept Gastrointestinal Surg, Fuzhou, Peoples R China; [Li, Xifeng; Zhang, Jin] Second Mil Med Univ, Affiliated Hosp 3, Dept Hepat Surg, Shanghai, Peoples R China; [Zheng, Jiaping] Zhejiang Canc Hosp, Dept Intervent Radiol, Hangzhou, Peoples R China; [Xin, Jianjun] Qingdao Cent Med Grp, Dept Gastrointestinal Surg, Qingdao, Peoples R China; [Huang, Bin] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Hunan Canc Hosp,Dept Intervent Radiol, Changsha, Peoples R China; [Zhu, Guopei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Radiat Oncol, Shanghai, Peoples R China; [Zhu, Jiexiang] Jiangsu Hengrui Pharmaceut Co Ltd, Dept Med Affairs, Shanghai, Peoples R China"

通信作者："Liang, J (通讯作者)，Peking Univ, Int Hosp, Dept Oncol, 1 Life Pk Rd,Life Sci Pk Zhongguancun, Beijing 102206, Peoples R China."

来源：BMC CANCER

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001302565300001

JCR分区：Q2

影响因子：3.8

年份：2024

卷号：24

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Apatinib; Cancer; Depression; Insomnia; Survey

摘要："BackgroundData on long-term cancer survivors treated with apatinib are lacking. This study aimed to describe the characteristics of long-term cancer survivors after apatinib-based therapy, and to know about their satisfaction degree with apatinib and severity of depression and insomnia.MethodsPatients with solid tumors who had received apatinib-based therapy for at least 5 years were invited to complete an online questionnaire. Characteristics of patients and treatment, knowledge of apatinib, satisfaction degree, and severity of depression and insomnia assessed by Patient Health Questionnaire-9 and Insomnia Severity Index were collected.ResultsBetween December 8, 2023 and March 1, 2024, a total of 436 patients completed the online questionnaire. Most patients were satisfied with the efficacy (96.6%) and safety (93.1%) of apatinib, were willing to continue apatinib treatment (99.5%), and would recommend apatinib to other patients (93.3%). Continuous apatinib treatment resulted in significant negative impact on daily life, work, or study in only two (0.5%) patients. Almost all patients currently had no or mild depression (97.0%) and insomnia (97.9%) problems. The most common patient-reported adverse events were hand-foot syndrome (21.3%) and hypertension (18.3%).ConclusionsOur survey showed a high satisfaction degree with apatinib in long-term cancer survivors. Long-term apatinib treatment resulted in almost no negative impact on patient's quality of life."

基金机构："Jiangsu Hengrui Pharmaceuticals Co., Ltd."

基金资助正文："We thank all patients participating in this survey. We also thank Fangzhou Xia (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.) for medical writing assistance."